rosiglitazone has been researched along with gw 501516 in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (46.15) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, WH; Burns, M; Chen, L; Claus, T; Daly, M; Dela Cruz, FE; Ehrgott, FJ; Johnson, JS; Livingston, JN; Ma, X; Majumdar, D; Rudolph, J; Schoenleber, RW; Shapiro, J; Tsutsumi, M; Yang, L | 1 |
| Daugaard, JR; Fleckner, J; Galsgaard, ED; Havranek, M; Jeppesen, CB; Jeppesen, L; Mogensen, JP; Olsen, GS; Panajotova, V; Pettersson, I; Pihera, P; Polivka, Z; Sauerberg, P; Wulff, EM; Ynddal, L | 1 |
| Havranek, M; Jeppesen, CB; Kratina, P; Mogensen, JP; Pettersson, I; Pihera, P; Sauerberg, P | 1 |
| Ebdrup, S; Havranek, M; Jeppesen, CB; Johansson, E; Korínek, M; Mogensen, JP; Pettersson, I; Pihera, P; Sauerberg, P | 1 |
| Amatruda, J; Bullock, W; Burns, M; Cantin, LD; Chuang, CY; Claus, T; Dai, M; Dela Cruz, F; Dickson, D; Ehrgott, FJ; Fan, D; Heald, S; Hentemann, M; Iwuagwu, CI; Johnson, JS; Kumarasinghe, E; Ladner, D; Lavoie, R; Liang, S; Livingston, JN; Lowe, D; Ma, X; Magnuson, S; Mannelly, G; Mugge, I; Ogutu, H; Pleasic-Williams, S; Schoenleber, RW; Shapiro, J; Shelekhin, T; Sweet, L; Town, C; Tsutsumi, M; Wickens, P; Zhang, C; Zhao, Q | 1 |
| Giri, S; Goel, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Pingali, H; Shah, S; Zaware, P | 1 |
| Basu, S; Giri, S; Godha, A; Goel, A; Goswami, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Patil, P; Pingali, H; Shah, S; Zaware, P | 1 |
| de Lera, AR; Otero, MP; Pérez Santín, E; Rodríguez-Barrios, F; Vaz, B | 1 |
| Endo, T; Kanda, T; Nakamura, H; Sakuma, S; Yamakawa, T; Yamasaki, S | 2 |
| Bahekar, R; Giri, S; Jain, M; Jamili, J; Makadia, P; Patel, D; Patel, H; Patel, L; Patel, P; Pingali, H; Pola, S; Priyadarshini, P; Sairam, KV; Shah, M; Shah, SR; Sudani, H; Suthar, D; Thube, B; Zaware, P | 1 |
| Bahekar, R; Giri, S; Jain, M; Makadia, P; Patel, D; Patel, P; Pingali, H; Pola, S; Priyadarshini, P; Shah, M; Shah, SR; Suthar, D; Thube, B; Trivedi, C; Zaware, P | 1 |
| Ciocoiu, CC; Hansen, TV; Ravna, AW; Rustan, AC; Sylte, I | 1 |
| Gege, C; Hoffmann, T; Schlüter, T | 1 |
| Hashimoto, Y; Ishikawa, M; Makishima, M; Noguchi-Yachide, T; Okazaki, S; Sakai, T; Yamaguchi, T | 1 |
| Hashimoto, Y; Ishikawa, M; Makishima, M; Noguchi-Yachide, T; Okazaki, S; Shioi, R; Yamaguchi, T | 2 |
| Gu, YH; Hou, DL; Li, HB; Liu, K; Qi, X; Xu, QL; Zhao, X | 1 |
| Fukasawa, H; Itai, A; Kato, T; Matsumura, KI; Mizutani, M; Muto, S; Ohara, T; Suzuki, N; Tokuyama, R | 1 |
| Balaguer, P; Carlavan, I; Lemaire, G; Nicolas, JC; Perrin, A; Pillon, A; Seimandi, M; Vignon, F; Voegel, JJ | 1 |
| Johnson, TE; Shi, S; Umbenhauer, DR; Zhang, X | 1 |
| De Windt, LJ; Smeets, PJ; Teunissen, BE; Van Bilsen, M; Van der Vusse, GJ; Willemsen, PH | 1 |
| Gosker, HR; Langen, RC; Remels, AH; Russell, AP; Schols, AM; Schrauwen, P; Spaapen, F; Voncken, JW | 1 |
| Artis, DR; Bollag, G; Erbe, DV; Gareski, T; Gartrell, K; Harding, K; Ibrahim, PN; Jalenak, M; Kubasiak, D; Lin, JJ; Mansour, TS; Panza, D; Perreault, M; Saiah, E; Tobin, JF; Vlasuk, GP; Wang, S; Will, S; Womack, P | 1 |
| Baatjes, AJ; Campbell, H; Dua, B; Gauvreau, GM; Hill, M; Howie, K; Oliveria, JP; Sehmi, R; Smith, SG; Watson, BM; Watson, RM | 1 |
| Astakhova, AA; Chistyakov, DV; Goriainov, SV; Sergeeva, MG | 1 |
26 other study(ies) available for rosiglitazone and gw 501516
| Article | Year |
|---|---|
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
Topics: Acetates; Animals; Apolipoprotein A-I; Cell Line; Cricetinae; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; In Vitro Techniques; Indans; Lipids; Male; Mice; Mice, Transgenic; PPAR alpha; PPAR delta; PPAR gamma; Radioligand Assay; Rats; Rats, Zucker; Solubility; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation; Triazoles | 2007 |
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
Topics: Administration, Oral; Allyl Compounds; Animals; Apolipoprotein B-100; Binding Sites; Cell Line; Cholesterol Ester Transfer Proteins; Crystallography, X-Ray; Dietary Fats; Fatty Acids, Nonesterified; Female; Humans; Lipid Metabolism; Male; Mice; Mice, Transgenic; Models, Molecular; Muscle, Skeletal; Oxidation-Reduction; Phenylacetates; PPAR delta; Rats; Structure-Activity Relationship; Transcriptional Activation | 2007 |
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.
Topics: Models, Molecular; Molecular Structure; PPAR delta | 2007 |
Design of a partial PPARdelta agonist.
Topics: Butyrates; Drug Design; Models, Molecular; Molecular Structure; Phenylurea Compounds; PPAR delta; Structure-Activity Relationship; Thiazoles | 2007 |
Indanylacetic acids as PPAR-delta activator insulin sensitizers.
Topics: Fluorescence Resonance Energy Transfer; Insulin Resistance; PPAR delta; Structure-Activity Relationship | 2007 |
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
Topics: Animals; Carboxylic Acids; Diabetes Mellitus; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred NOD; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Structure-Activity Relationship | 2008 |
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
Topics: Animals; Carboxylic Acids; Diabetes Mellitus, Type 2; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Mesylates; Mice; Models, Chemical; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Transcriptional Activation | 2008 |
Selective, potent PPARgamma agonists with cyclopentenone core structure.
Topics: Cell Line; Computer Simulation; Cyclopentanes; HeLa Cells; Humans; PPAR gamma; Structure-Activity Relationship | 2009 |
Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.
Topics: Animals; Brain; Cell Differentiation; Humans; Isoxazoles; Multiple Sclerosis; Oligodendroglia; Oxazoles; PPAR delta; Rats; Transcriptional Activation | 2011 |
Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
Topics: Animals; Carboxylic Acids; Cell Line; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Oximes; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Wistar; Structure-Activity Relationship | 2011 |
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
Topics: Animals; Cricetinae; Disease Models, Animal; Ether; Hep G2 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Obese; Oximes; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Structure-Activity Relationship; Thiazoles | 2011 |
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
Topics: Animals; Cell Differentiation; Cell Line; Cells, Cultured; Cerebral Cortex; Humans; Isoxazoles; Oligodendroglia; PPAR delta; Rats; Rats, Wistar | 2011 |
Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.
Topics: Cells, Cultured; Humans; Hydrocarbons, Fluorinated; Models, Molecular; Muscle Cells; Muscle, Skeletal; PPAR alpha; Protein Binding; Thiazoles | 2011 |
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
Topics: Benzeneacetamides; Drug Inverse Agonism; Fluorescence Resonance Energy Transfer; Humans; Ligands; Nuclear Receptor Subfamily 1, Group F, Member 2; Nuclear Receptor Subfamily 1, Group F, Member 3; Protein Binding; Th17 Cells; Thiazoles; Tretinoin | 2014 |
Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonistic activity.
Topics: Acetamides; Acetyl-CoA Carboxylase; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Molecular Structure; Oxadiazoles; PPAR alpha; PPAR delta; Structure-Activity Relationship | 2016 |
Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Topics: Acetamides; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Molecular Structure; PPAR alpha; PPAR delta; Structure-Activity Relationship | 2016 |
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Topics: Acetamides; Binding Sites; Genes, Reporter; HEK293 Cells; Humans; Ligands; PPAR alpha; PPAR delta; Protein Binding; Stereoisomerism; Thiazolidinediones | 2017 |
Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypoglycemic Agents; Male; Molecular Structure; NF-kappa B; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Streptozocin; Structure-Activity Relationship | 2021 |
Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
Topics: Benzothiazoles; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Molecular Structure; PPAR alpha; PPAR delta; PPAR gamma; Structure-Activity Relationship | 2022 |
Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
Topics: Anilides; Benzhydryl Compounds; Butyrates; DNA-Binding Proteins; Epoxy Compounds; Genes, Reporter; HeLa Cells; Humans; Inhibitory Concentration 50; Ligands; Luciferases; Peroxisome Proliferator-Activated Receptors; Phenylurea Compounds; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Saccharomyces cerevisiae Proteins; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 2005 |
Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.
Topics: Adenosine Triphosphate; Animals; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Induction; Fibrinolytic Agents; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ion Channels; Membrane Transport Proteins; Mitochondrial Proteins; Muscle Fibers, Skeletal; Muscular Diseases; Myoblasts, Skeletal; Peroxisome Proliferator-Activated Receptors; Pyrimidines; Rats; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Uncoupling Protein 2 | 2005 |
Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts.
Topics: Animals; Animals, Newborn; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Fibroblasts; Fibrosis; Humans; Immunohistochemistry; Ligands; Myocytes, Cardiac; Peroxisome Proliferators; PPAR alpha; PPAR delta; PPAR gamma; Pyrimidines; Rats; Rats, Inbred Lew; Rosiglitazone; Thiazoles; Thiazolidinediones; Transduction, Genetic | 2007 |
PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle.
Topics: Animals; Cells, Cultured; Cytokines; Down-Regulation; Humans; Hypoglycemic Agents; Inflammation Mediators; Male; Mice; Middle Aged; Muscle, Skeletal; NF-kappa B; PPAR gamma; Pyrimidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcriptional Activation | 2009 |
Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.
Topics: Animals; Appetite Depressants; Appetite Regulation; Energy Metabolism; Insulin Resistance; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Loss | 2010 |
Evaluation of peroxisome proliferator-activated receptor agonists on interleukin-5-induced eosinophil differentiation.
Topics: Adolescent; Adult; Aged; Butyrates; Cell Differentiation; Dose-Response Relationship, Drug; Eosinophils; Female; Humans; Interleukin-5; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Phenylurea Compounds; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Young Adult | 2014 |
Comparison of PPAR Ligands as Modulators of Resolution of Inflammation, via Their Influence on Cytokines and Oxylipins Release in Astrocytes.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Astrocytes; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Interleukin-10; Lipopolysaccharides; MAP Kinase Kinase 4; Oxazoles; Oxylipins; p38 Mitogen-Activated Protein Kinases; PPAR gamma; PPAR-beta; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Tumor Necrosis Factor-alpha; Tyrosine | 2020 |